Truist Securities Maintains Buy on Insmed, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Buy rating on Insmed and raised its price target from $85 to $100, indicating confidence in the company's future performance.
October 11, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has increased its price target for Insmed from $85 to $100, maintaining a Buy rating. This suggests a positive outlook for Insmed's stock performance.
The increase in price target from $85 to $100 by Truist Securities, along with the maintained Buy rating, indicates strong confidence in Insmed's future performance. This is likely to positively influence investor sentiment and could lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100